ALLO vs APH · rev $22.0K vs P/E 40, rev $23.09B
Allogene Therapeutics Inc (ALLO) versus Amphenol Corporation (APH) — a side-by-side from cached financials, not a winner call.
Allogene Therapeutics Inc (ALLO) is a biotechnology company listed on US.
Amphenol Corporation (APH) is a electronic components company listed on US.
Latest reported ALLO revenue for 2024-12-31 was $22.0K. Net income was -$257.6M. Revenue was down 76.8% from 2023-12-31 to 2024-12-31. ALLO currently screens at market cap $258.1M.
Latest reported APH revenue for 2025-12-31 was $23.09B. Net income was $4.27B. Revenue was up 51.7% from 2024-12-31 to 2025-12-31. APH currently screens at market cap $170.77B and trailing P/E 39.9.
ALLO currently screens at market cap $258.1M. APH currently screens at market cap $170.77B and trailing P/E 39.9.
Not investment advice. Open the ALLO and APH stock pages for the full models.
Not investment advice.